How Zevra’s Miplyffa Could Transform Investment Strategies

All NewsJuly 2, 2025

HC Wainwright sees Zevra’s Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy rating on rare disease strength.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent